Enovis Corp
$ 22.29
-2.60%
25 Feb - close price
- Market Cap 1,308,493,000 USD
- Current Price $ 22.29
- High / Low $ 22.98 / 21.87
- Stock P/E N/A
- Book Value 35.33
- EPS -24.36
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE -0.51 %
- 52 Week High 40.70
- 52 Week Low 21.00
About
Enovis Corporation is a global medical technology company. The company is headquartered in Wilmington, Delaware.
Analyst Target Price
$45.09
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-04-30 | 2025-02-20 | 2024-11-06 | 2024-08-07 | 2024-05-02 | 2024-02-22 | 2023-11-07 | 2023-08-03 | 2023-05-04 | 2023-02-23 |
| Reported EPS | 0.75 | 0.79 | 0.81 | 0.98 | 0.73 | 0.62 | 0.5 | 0.79 | 0.56 | 0.61 | 0.44 | 0.72 |
| Estimated EPS | 0.65 | 0.7187 | 0.7438 | 0.9157 | 0.62 | 0.59 | 0.48 | 0.74 | 0.54 | 0.52 | 0.37 | 0.66 |
| Surprise | 0.1 | 0.0713 | 0.0662 | 0.0643 | 0.11 | 0.03 | 0.02 | 0.05 | 0.02 | 0.09 | 0.07 | 0.06 |
| Surprise Percentage | 15.3846% | 9.9207% | 8.9002% | 7.022% | 17.7419% | 5.0847% | 4.1667% | 6.7568% | 3.7037% | 17.3077% | 18.9189% | 9.0909% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.81 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $0.0 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ENOV
2026-02-25 14:57:54
Enovis Corporation (NYSE:ENOV) is set to report its earnings tomorrow before the market open. The company previously surpassed analysts' revenue expectations, reporting $548.9 million, an 8.6% year-on-year increase. Analysts anticipate a 4.1% year-on-year revenue growth this quarter.
2026-02-23 17:00:00
Shares of several companies including Integra LifeSciences, Enovis, BrightSpring Health Services, IQVIA, and Charles River Laboratories plummeted after the Trump administration announced new global tariffs. These tariffs, imposed under the Trade Act of 1974, have created significant uncertainty for companies reliant on international supply chains. Investors are now assessing the potential impact of these duties on corporate earnings and the broader economy, leading to sharp declines in the stock prices of the affected companies.
2026-02-19 11:26:40
First National Bank of Omaha has acquired 73,248 shares of Enovis Corporation, a medical technology company, for approximately $2.22 million, representing a new position and 0.13% ownership. Institutional investors now hold about 98.45% of Enovis stock, while analysts have a "Moderate Buy" rating with an average target price significantly higher than current trading levels. Insider activity shows mixed signals, with a director buying shares and an EVP selling.
2026-02-19 07:57:24
Enovis (ENOV) is scheduled to release its Q4 2025 earnings before market open on Thursday, February 26th, with analysts anticipating $0.81 EPS and $584.3 million in revenue. The stock opened at $22.08, reflecting a 2.1% increase, and has a "Moderate Buy" consensus rating from Wall Street analysts with an average price target of $46.71. Insider transactions show recent buying and selling activity, while institutional ownership stands at a high 98.45%.
2026-02-17 17:27:49
Enovis Corporation (ENOV), a medical device company, shows a significant 107.12% upside potential, with analysts issuing 11 "buy" ratings despite recent stock declines and negative EPS and ROE. The company's robust free cash flow and strategic market positioning in orthopedic solutions are highlighted as key strengths, suggesting a strong recovery and growth trajectory for patient investors. Technical indicators also point to an oversold stock, potentially offering a buying opportunity.
2026-02-12 10:27:33
Impax Asset Management Group plc increased its stake in Enovis Corporation (NYSE:ENOV) by 47.5% in the third quarter, acquiring an additional 100,000 shares to own a total of 310,630 shares valued at $9.425 million. This report also details other hedge fund activities, insider transactions, and analyst ratings for Enovis, which highlight a "Moderate Buy" consensus and an average price target of $46.71. The company's stock trades at $22.77, with a market capitalization of $1.30 billion.
